Rocket Pharmaceuticals shareholders approve stock option exchange program at annual meeting

Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc.

RCKT

0.00
  • Rocket Pharmaceuticals held its annual stockholders meeting on May 20, 2026.
  • Shareholders backed the slate of seven director nominees for board seats.
  • EisnerAmper LLP was ratified as independent registered accounting firm for the fiscal year ending Dec. 31, 2026.
  • Shareholders authorized a stock option exchange program, clearing the way for implementation under the terms described in the proxy materials.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rocket Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-022311), on May 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.